Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Study of Evaluating the Efficacy and Safety of CM326 in Subjects With Moderate to Severe Asthma

NCT07372287 is registered in ClinicalTrials.gov with CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07372287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07372287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Study of Evaluating the Efficacy and Safety of CM326 in Subjects With Moderate to Severe Asthma
Lead sponsor
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
January 23, 2026
Completion date
March 31, 2029
Enrollment
230 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe asthma